Luma Vision announced today that it raised $22 million to support its bid for FDA clearance of its Verafeye imaging and navigation platform.
The company, headquartered in Dublin, Ireland, and Munich, Germany, develops novel four-dimensional (4D) technology. It designed Verafeye for cardiac imaging and navigation and has plans to build next-generation versions for additional applications.
Verafeye features data-driven software applications and a proprietary catheter sensor with advanced digital imaging and deep learning. Luma Vision says it provides high-resolution, 360-degree imagery of the beating heart and surrounding anatomy. It can be used with other catheters or systems during cardiac surgery.
With multiple applications in one platform, Verafeye can provide all imaging guidance needed during cardiac surgery in real-time. It eliminates the need for external systems like X-ray or CT as well.
Luma Vision said in a news release that Verafeye can …